BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Athersys begins Phase I trial for ATHX-105 for treatment of obesity
News | 07. 25. 2007
Athersys
Athersys, Inc., a wholly owned subsidiary of BTHC VI (OTC Bulletin Board: BVIC), announced today that it has initiated a Phase I clinical trial in the United Kingdom for ATHX-105, the company’s oral, selective 5HT2c receptor agonist for treating obesity.
